Skip to content

Vaxcyte, Inc. PCVX Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Merck & Co. logo
Merck & Co.MRK
20M0.0%
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s convertible preferred stock authorized shares?
Vaxcyte, Inc. (PCVX) reported convertible preferred stock authorized shares of 10M in Q1 2026.
How has Vaxcyte, Inc.'s convertible preferred stock authorized shares changed year-over-year?
Vaxcyte, Inc.'s convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 10M to 10M.
What is the long-term trend for Vaxcyte, Inc.'s convertible preferred stock authorized shares?
Over 2 years (2023 to 2025), Vaxcyte, Inc.'s convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 10M to 10M.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.